Last updated on August 2019

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Psoriasis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Participant has diagnosis of chronic plaque psoriasis for at least 6 months before the baseline visit.
  • Participant meets following disease activity criteria:
  • Stable moderate to severe chronic plaque psoriasis, defined as greater than or equal to 10% body surface area (BSA) psoriasis involvement, static physician global assessment (sPGA) score of greater than or equal to 3, and Psoriasis Area Severity Index (PASI) greater than or equal to 12 at Screening and baseline visit.
  • Candidate for systemic therapy as assessed by the investigator.

Exclusion Criteria:

  • Participant has history of active skin disease other than psoriasis that could interfere with the assessment of psoriasis.
  • Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis.
  • Participant has previous exposure to risankizumab.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.